Arcturus Therapeutics Holdings (ARCT) Current Deferred Revenue (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Current Deferred Revenue data on file, last reported at $7.6 million in Q1 2026.

• Quarterly Current Deferred Revenue fell 39.94% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (down 39.94% YoY) and the FY2025 annual result came in at $8.2 million, down 57.74% from the prior year.
• Current Deferred Revenue eased to $7.6 million in Q1 2026, from $8.2 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $71.5 million in Q1 2024 to a low of $4.7 million in Q3 2022.
• A 5-year average of $28.9 million and a median of $26.9 million in 2024 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue slumped 91.92% — and 2023, when it soared 775.6%.
• Tracing ARCT's Current Deferred Revenue over 5 years: stood at $28.6 million in 2022, then soared by 56.48% to $44.8 million in 2023, then plunged by 56.47% to $19.5 million in 2024, then sank by 57.74% to $8.2 million in 2025, then fell by 7.71% to $7.6 million in 2026.
• The last three Current Deferred Revenue figures came in at $7.6 million (Q1 2026), $8.2 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.